Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
about
Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathwayCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsInhibition of class II phosphoinositide 3-kinase gamma expression by p185(Bcr-Abl) contributes to impaired chemotaxis and aberrant homing of leukemic cellsA novel BCR-ABL1 fusion gene with genetic heterogeneity indicates a good prognosis in a chronic myeloid leukemia case.Biology-driven cancer drug development: back to the futureImatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesCD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinFTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.Philadelphia positive acute lymphoblastic leukaemia of childhood.ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.Hematopoietic growth factors, signaling and the chronic myeloproliferative disorders.Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.Transcription and signalling pathways involved in BCR-ABL-mediated misregulation of 24p3 and 24p3RAurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity.Management options for refractory chronic myeloid leukemia: considerations for the elderly.Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.Genomic characterization of acute leukemias.New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia.Chronic myeloid leukemia: past, present, future.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia.Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.Genetic aberrations in childhood acute lymphoblastic leukaemia: application of high-density single nucleotide polymorphism array.Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.Genomic instability in chronic myeloid leukemia: targets for therapy?
P2860
Q24676463-58D33F7F-F1CF-49B4-85BC-672436DA9287Q26778929-1803DA42-E111-4D92-BD04-A1C69BC714B5Q28512494-CDCD1A4D-3FDD-456D-A91B-716DB75F3F36Q30152631-7D2D63AB-EA14-44E6-84D1-352B378BD4C8Q33552888-9708A354-33BC-44A7-ADCA-9F92627112CCQ33557847-91CACF40-5228-4603-867E-BB2A9252EEF7Q33688509-F95716C3-033A-4ACB-8829-FBD4C545CA08Q34139691-8DD1D100-1050-4D4F-85E0-155D47A80E10Q35717808-50043A52-93F6-4F0F-8778-13EA3E7534BCQ35945171-0224958C-6F91-4B1B-BB20-18113DECBA2BQ36228062-4ED05858-6CA4-497A-8B8F-B0164FFFA565Q36585748-E52FB44D-808A-4A58-B021-E5F319F035CEQ36630747-657C674C-3D66-4912-BFAF-8DEC0E5E51BFQ36857947-68FDCE1E-22DE-4E81-AE4A-D02AC6C6A56DQ37163039-E4BD9DD5-B4DA-40BD-90EB-3649C72EF9C5Q37399824-0C45A493-72CB-4593-9199-3E47CD7FD1B4Q37498272-39CCC444-CE60-4349-A4BF-0A5C673A6230Q37589123-8C418840-E098-40A4-8478-DD07D306F08FQ37781050-8F8199C9-C68D-4DED-99FB-140954726855Q38034270-8C0BCF6E-8DF3-4B46-ABEF-2281BC4C7563Q38101471-E316F82D-D023-47AE-8267-DA8FBAA1B082Q38193659-B95E0C74-E2F2-4C3B-B79D-0320CBBA2295Q38223490-26F28617-7B46-4029-934A-B4487BEC383BQ38252432-0ED11F96-07AC-4B1D-A26A-98E46C983088Q38694690-7C08E1C6-FB19-4236-9294-4F98DCC84866Q38707841-ED642E66-350F-4BCF-AF55-A44BFC5E3D78Q38723094-D0AB054C-094B-40D2-92EE-5F0FB1406012Q38814852-6062D105-3BDF-4A2F-96A5-29DCC0EB6977Q39010100-C298E7D9-0B5A-4582-B9B3-213FFF65281EQ39108890-7446217E-9078-4663-AF4D-A5A204C55764Q39294830-ED1F2D20-B6F8-409F-BE7A-A16F23790561Q39308078-D27822DC-A1E2-4190-96F8-0E5E3EF5430CQ39316870-341F132F-CA8B-42FB-9370-6EA58AF2EB5EQ39962747-3E94927B-9666-4F64-92E6-4EC2447E4DA2Q40047397-F87CF826-D1EB-45DE-B118-563B80C522E5Q40321847-1AD13651-3005-4324-92B4-CB7C5F39E134Q43078241-3832DC87-0189-4167-A0CC-7986FECB91BAQ47210315-638536B8-5841-4FE3-86AA-917317398BC4Q49888044-DB57F19D-FBBD-4DFC-9F4A-AE6B272B1A14Q53272675-039B2631-EDD6-4153-91AF-318270B1918B
P2860
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Biology of chronic myelogenous ...... initiation and transformation.
@ast
Biology of chronic myelogenous ...... initiation and transformation.
@en
type
label
Biology of chronic myelogenous ...... initiation and transformation.
@ast
Biology of chronic myelogenous ...... initiation and transformation.
@en
prefLabel
Biology of chronic myelogenous ...... initiation and transformation.
@ast
Biology of chronic myelogenous ...... initiation and transformation.
@en
P1476
Biology of chronic myelogenous ...... initiation and transformation.
@en
P2093
Junia V Melo
Michael W N Deininger
P304
545-68, vii-viii
P356
10.1016/J.HOC.2004.03.008
P577
2004-06-01T00:00:00Z